Salbutamol/budesonide

Last updated

Salbutamol/budesonide
Combination of
Albuterol short-acting β2-agonist
Budesonide inhaled corticosteroid
Clinical data
Trade names Airsupra
Other namesPT027, albuterol/budesonide
AHFS/Drugs.com Monograph
License data
Routes of
administration 		Inhalation
ATC code
Legal status
Legal status
Identifiers
KEGG

Albuterol/budesonide, sold under the brand name AIRSUPRA, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma. [1] [2] It is a combination of albuterol, a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid. [1] [2] It is inhaled using a pressurized metered-dose inhaler. [1] [2]

Contents

The most common side effects include headache, oral candidiasis, cough, and difficulty speaking. [2]

AIRSUPRA was approved for medical use in the United States in January 2023. [2] [3] It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved by the US Food and Drug Administration (FDA). [2] It is the first product containing an inhaled corticosteroid to be approved by the FDA as a reliever treatment (rather than as a controller) for asthma. [2]

Medical uses

AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks. [1] [2]

History

The efficacy of salbutamol/budesonide to reduce the risk of severe asthma attacks was evaluated in participants with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study. [2]

References

  1. 1 2 3 4 5 "Airsupra- albuterol sulfate and budesonide aerosol, metered". DailyMed. 7 March 2024. Retrieved 16 May 2024.
  2. 1 2 3 4 5 6 7 8 9 "FDA approves drug combination treatment for adults with asthma". U.S. Food and Drug Administration. 11 January 2023. Archived from the original on 20 January 2023. Retrieved 20 January 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  3. ↑ "Airsupra (PT027) approved in the US for asthma". AstraZeneca (Press release). 11 January 2023. Archived from the original on 20 January 2023. Retrieved 20 January 2023.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.